Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Caserta E, Chea J, Minnix M, Viola D, Vonderfecht S, Yazaki P, Crow D, Khalife J, Sanchez JF, Palmer JM, Hui S, Carlesso N, Keats J, Kim Y, Buettner R, Marcucci G, Rosen S, Shively J, Colcher D, Krishnan A, Pichiorri F.

Blood. 2018 Feb 15;131(7):741-745. doi: 10.1182/blood-2017-09-807263. Epub 2018 Jan 4.

PMID:
29301755
2.

miR-146a-Traf6 regulatory axis controls autoimmunity and myelopoiesis, but is dispensable for hematopoietic stem cell homeostasis and tumor suppression.

Magilnick N, Reyes EY, Wang WL, Vonderfecht SL, Gohda J, Inoue JI, Boldin MP.

Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7140-E7149. doi: 10.1073/pnas.1706833114. Epub 2017 Aug 7.

3.

Identification of neuron selective androgen receptor inhibitors.

Otto-Duessel M, Tew BY, Vonderfecht S, Moore R, Jones JO.

World J Biol Chem. 2017 May 26;8(2):138-150. doi: 10.4331/wjbc.v8.i2.138.

4.

Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1.

Zhang X, Guo C, Wu X, Li AX, Liu L, Tsark W, Dammann R, Shen H, Vonderfecht SL, Pfeifer GP.

Cancer Res. 2016 May 1;76(9):2824-35. doi: 10.1158/0008-5472.CAN-15-3010. Epub 2016 Mar 15.

5.

Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model.

Ouyang M, White EE, Ren H, Guo Q, Zhang I, Gao H, Yanyan S, Chen X, Weng Y, Da Fonseca A, Shah S, Manuel ER, Zhang L, Vonderfecht SL, Alizadeh D, Berlin JM, Badie B.

PLoS One. 2016 Feb 1;11(2):e0148139. doi: 10.1371/journal.pone.0148139. eCollection 2016.

6.

Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotype.

Fu Y, Cruz-Monserrate Z, Helen Lin H, Chung Y, Ji B, Lin SM, Vonderfecht S, Logsdon CD, Li CF, Ann DK.

Sci Rep. 2015 Aug 20;5:13347. doi: 10.1038/srep13347.

7.

Altered lymphopoiesis and immunodeficiency in miR-142 null mice.

Kramer NJ, Wang WL, Reyes EY, Kumar B, Chen CC, Ramakrishna C, Cantin EM, Vonderfecht SL, Taganov KD, Chau N, Boldin MP.

Blood. 2015 Jun 11;125(24):3720-30. doi: 10.1182/blood-2014-10-603951. Epub 2015 Apr 30.

8.

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma.

Hamblett KJ, Kozlosky CJ, Siu S, Chang WS, Liu H, Foltz IN, Trueblood ES, Meininger D, Arora T, Twomey B, Vonderfecht SL, Chen Q, Hill JS, Fanslow WC.

Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.

9.

Development of 2-aminooxazoline 3-azaxanthenes as orally efficacious β-secretase inhibitors for the potential treatment of Alzheimer's disease.

Chen JJ, Liu Q, Yuan C, Gore V, Lopez P, Ma V, Amegadzie A, Qian W, Judd TC, Minatti AE, Brown J, Cheng Y, Xue M, Zhong W, Dineen TA, Epstein O, Human J, Kreiman C, Marx I, Weiss MM, Hitchcock SA, Powers TS, Chen K, Wen PH, Whittington DA, Cheng AC, Bartberger MD, Hickman D, Werner JA, Vargas HM, Everds NE, Vonderfecht SL, Dunn RT 2nd, Wood S, Fremeau RT Jr, White RD, Patel VF.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):767-74. doi: 10.1016/j.bmcl.2014.12.092. Epub 2015 Jan 8.

PMID:
25613679
10.

Dynamic involvement of ATG5 in cellular stress responses.

Lin HH, Lin SM, Chung Y, Vonderfecht S, Camden JM, Flodby P, Borok Z, Limesand KH, Mizushima N, Ann DK.

Cell Death Dis. 2014 Oct 23;5:e1478. doi: 10.1038/cddis.2014.428.

11.

Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes.

Chen B, Chen X, Wu X, Wang X, Wang Y, Lin TY, Kurata J, Wu J, Vonderfecht S, Sun G, Huang H, Yee JK, Hu J, Lin RJ.

Cancer Lett. 2015 Jan 28;356(2 Pt B):506-516. doi: 10.1016/j.canlet.2014.09.034. Epub 2014 Oct 7.

12.

Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy.

Beltran PJ, Calzone FJ, Mitchell P, Chung YA, Cajulis E, Moody G, Belmontes B, Li CM, Vonderfecht S, Velculescu VE, Yang G, Qi J, Slamon DJ, Konecny GE.

Clin Cancer Res. 2014 Jun 1;20(11):2947-58. doi: 10.1158/1078-0432.CCR-13-3448. Epub 2014 Apr 11.

13.

Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.

Ashton KS, Andrews KL, Bryan MC, Chen J, Chen K, Chen M, Chmait S, Croghan M, Cupples R, Fotsch C, Helmering J, Jordan SR, Kurzeja RJ, Michelsen K, Pennington LD, Poon SF, Sivits G, Van G, Vonderfecht SL, Wahl RC, Zhang J, Lloyd DJ, Hale C, St Jean DJ Jr.

J Med Chem. 2014 Jan 23;57(2):309-24. doi: 10.1021/jm4016735. Epub 2014 Jan 9. Erratum in: J Med Chem. 2014 Mar 27;57(6):2820. Bryan, Marion C [corrected to Bryan, Marian C].

PMID:
24405172
14.

Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.

Lloyd DJ, St Jean DJ Jr, Kurzeja RJ, Wahl RC, Michelsen K, Cupples R, Chen M, Wu J, Sivits G, Helmering J, Komorowski R, Ashton KS, Pennington LD, Fotsch C, Vazir M, Chen K, Chmait S, Zhang J, Liu L, Norman MH, Andrews KL, Bartberger MD, Van G, Galbreath EJ, Vonderfecht SL, Wang M, Jordan SR, Véniant MM, Hale C.

Nature. 2013 Dec 19;504(7480):437-40. doi: 10.1038/nature12724. Epub 2013 Nov 13.

PMID:
24226772
15.

Androgen (dihydrotestosterone)-mediated regulation of food intake and obesity in female mice.

Kanaya N, Vonderfecht S, Chen S.

J Steroid Biochem Mol Biol. 2013 Nov;138:100-6. doi: 10.1016/j.jsbmb.2013.04.001. Epub 2013 May 7.

16.

Inhibition of WISE preserves renal allograft function.

Qian X, Yuan X, Vonderfecht S, Ge X, Lee J, Jurisch A, Zhang L, You A, Fitzpatrick VD, Williams A, Valente EG, Pretorius J, Stevens JL, Tipton B, Winters AG, Graham K, Harriss L, Baker DM, Damore M, Salimi-Moosavi H, Gao Y, Elkhal A, Paszty C, Simonet WS, Richards WG, Tullius SG.

J Am Soc Nephrol. 2013 Jan;24(1):66-76. doi: 10.1681/ASN.2012010012. Epub 2012 Nov 26.

17.

FGF21 promotes metabolic homeostasis via white adipose and leptin in mice.

Véniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, Vonderfecht S, Xu J, Lloyd DJ.

PLoS One. 2012;7(7):e40164. doi: 10.1371/journal.pone.0040164. Epub 2012 Jul 6.

18.

Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism.

Ge H, Baribault H, Vonderfecht S, Lemon B, Weiszmann J, Gardner J, Lee KJ, Gupte J, Mookherjee P, Wang M, Sheng J, Wu X, Li Y.

PLoS One. 2012;7(3):e33603. doi: 10.1371/journal.pone.0033603. Epub 2012 Mar 23.

19.

A unique FGF23 with the ability to activate FGFR signaling through both αKlotho and βKlotho.

Wu X, Weiszmann J, Ge H, Baribault H, Stevens J, Hawkins N, Vonderfecht S, Gardner J, Gupte J, Sheng J, Wang M, Li Y.

J Mol Biol. 2012 Apr 20;418(1-2):82-9. doi: 10.1016/j.jmb.2012.02.027. Epub 2012 Feb 24.

PMID:
22370560
20.

Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat.

Wisler JA, Afshari C, Fielden M, Zimmermann C, Taylor S, Carnahan J, Vonderfecht S.

Toxicol Pathol. 2011 Aug;39(5):809-22. doi: 10.1177/0192623311410442. Epub 2011 Jun 15.

PMID:
21677315
21.

Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.

Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ.

J Pharmacol Exp Ther. 2011 Jun;337(3):644-54. doi: 10.1124/jpet.110.178400. Epub 2011 Mar 8.

22.

A novel statistical algorithm for gene expression analysis helps differentiate pregnane X receptor-dependent and independent mechanisms of toxicity.

Mongan MA, Dunn RT, Vonderfecht S, Everds N, Chen G, Su C, Higgins-Garn M, Chen Y, Afshari CA, Williamson TL, Carlock L, Dipalma C, Moss S, Bussiere J, Qualls C, He YD, Hamadeh HK.

PLoS One. 2010 Dec 21;5(12):e15595. doi: 10.1371/journal.pone.0015595.

23.

Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth.

Carnahan J, Beltran PJ, Babij C, Le Q, Rose MJ, Vonderfecht S, Kim JL, Smith AL, Nagapudi K, Broome MA, Fernando M, Kha H, Belmontes B, Radinsky R, Kendall R, Burgess TL.

Mol Cancer Ther. 2010 Aug;9(8):2399-410. doi: 10.1158/1535-7163.MCT-10-0181. Epub 2010 Jul 27.

24.

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).

Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, Gupte J, Gardner J, Lindberg R, Wang Z, Li Y.

Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14158-63. doi: 10.1073/pnas.1009427107. Epub 2010 Jul 26.

25.

FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation.

Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, Gupte J, Hager T, Wang Z, Lindberg R, Li Y.

J Biol Chem. 2010 Feb 19;285(8):5165-70. doi: 10.1074/jbc.M109.068783. Epub 2009 Dec 15.

26.

RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.

Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P.

Arthritis Res Ther. 2009;11(6):R187. doi: 10.1186/ar2879. Epub 2009 Dec 11.

27.

Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.

Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, Shen Y, Hu S, Boone T, Lindberg RA, Véniant MM.

J Pharmacol Exp Ther. 2009 Dec;331(3):871-81. doi: 10.1124/jpet.109.157685. Epub 2009 Aug 31.

28.

AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.

Beltran PJ, Mitchell P, Chung YA, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, Baserga R, Kendall R, Radinsky R, Calzone FJ.

Mol Cancer Ther. 2009 May;8(5):1095-105. doi: 10.1158/1535-7163.MCT-08-1171. Epub 2009 Apr 14.

29.

Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors.

Patyna S, Arrigoni C, Terron A, Kim TW, Heward JK, Vonderfecht SL, Denlinger R, Turnquist SE, Evering W.

Toxicol Pathol. 2008 Dec;36(7):905-16. doi: 10.1177/0192623308326151. Epub 2008 Nov 3.

PMID:
18981453
30.

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.

Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM.

Diabetes. 2009 Jan;58(1):250-9. doi: 10.2337/db08-0392. Epub 2008 Oct 7.

31.

Phospholipidosis in nonclinical toxicity studies.

Berridge BR, Chatman LA, Odin M, Schultze AE, Losco PE, Meehan JT, Peters T, Vonderfecht SL; Society of Toxicologic Pathology Scientific and Regulatory Policy Committee Working Group.

Toxicol Pathol. 2007 Feb;35(2):325. No abstract available.

PMID:
17366328
32.

Adoptive transfer of in vitro-stimulated CD4+CD25+ regulatory T cells increases bacterial clearance and improves survival in polymicrobial sepsis.

Heuer JG, Zhang T, Zhao J, Ding C, Cramer M, Justen KL, Vonderfecht SL, Na S.

J Immunol. 2005 Jun 1;174(11):7141-6.

33.

Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864.

Rudmann DG, McNerney ME, VanderEide SL, Schemmer JK, Eversole RR, Vonderfecht SL.

Toxicol Pathol. 2004 May-Jun;32(3):326-32.

PMID:
15204974
34.

Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence.

Vonderfecht SL, Stone ML, Eversole RR, Yancey MF, Schuette MR, Duncan BA, Ware JA.

Toxicol Pathol. 2004 May-Jun;32(3):318-25.

PMID:
15204973
35.

Reactive oxygen as modulator of TNF and fas receptor-mediated apoptosis in vivo: studies with glutathione peroxidase-deficient mice.

Bajt ML, Ho YS, Vonderfecht SL, Jaeschke H.

Antioxid Redox Signal. 2002 Oct;4(5):733-40.

PMID:
12470500
36.

Strategic importance of research support through pathology.

Cockerell GL, McKim JM, Vonderfecht SL.

Toxicol Pathol. 2002 Jan-Feb;30(1):4-7. Review.

PMID:
11890474
37.
38.
39.

Involvement of intercellular adhesion molecule-1 in the antigen-induced infiltration of eosinophils and lymphocytes into the airways in a murine model of pulmonary inflammation.

Chin JE, Winterrowd GE, Hatfield CA, Brashler JR, Griffin RL, Vonderfecht SL, Kolbasa KP, Fidler SF, Shull KL, Krzesicki RF, Ready KA, Dunn CJ, Sly LM, Staite ND, Richards IM.

Am J Respir Cell Mol Biol. 1998 Feb;18(2):158-67.

PMID:
9476902
40.
41.

Airway recruitment of leukocytes in mice is dependent on alpha4-integrins and vascular cell adhesion molecule-1.

Chin JE, Hatfield CA, Winterrowd GE, Brashler JR, Vonderfecht SL, Fidler SF, Griffin RL, Kolbasa KP, Krzesicki RF, Sly LM, Staite ND, Richards IM.

Am J Physiol. 1997 Feb;272(2 Pt 1):L219-29.

PMID:
9124372
42.

Role of intercellular adhesion molecule-1 in antigen-induced lung inflammation in brown Norway rats.

Richards IM, Kolbasa KP, Winterrowd GE, Hatfield CA, Vonderfecht SL, Fidler SF, Griffin RL, Brashler JR, Krzesicki RF, Lane CL, Anderson DC, Sly LM, Staite ND, Chin JE.

Am J Physiol. 1996 Aug;271(2 Pt 1):L267-76.

PMID:
8770066
43.

Role of very late activation antigen-4 in the antigen-induced accumulation of eosinophils and lymphocytes in the lungs and airway lumen of sensitized brown Norway rats.

Richards IM, Kolbasa KP, Hatfield CA, Winterrowd GE, Vonderfecht SL, Fidler SF, Griffin RL, Brashler JR, Krzesicki RF, Sly LM, Ready KA, Staite ND, Chin JE.

Am J Respir Cell Mol Biol. 1996 Aug;15(2):172-83.

PMID:
8703473
44.

Phenotypic analysis of airway eosinophils and lymphocytes in a Th-2-driven murine model of pulmonary inflammation.

Watkins AD, Hatfield CA, Fidler SF, Winterrowd GE, Brashler JR, Sun FF, Taylor BM, Vonderfecht SL, Conder GA, Holgate ST, Chin JE, Richards IM.

Am J Respir Cell Mol Biol. 1996 Jul;15(1):20-34.

PMID:
8679219
45.

Release of soluble intercellular adhesion molecule 1 into bile and serum in murine endotoxin shock.

Jaeschke H, Essani NA, Fisher MA, Vonderfecht SL, Farhood A, Smith CW.

Hepatology. 1996 Mar;23(3):530-6.

PMID:
8617433
46.

Borna disease virus p24 and p38/40 synthesized in a baculovirus expression system: virus protein interactions in insect and mammalian cells.

Hsu TA, Carbone KM, Rubin SA, Vonderfecht SL, Eiden JJ.

Virology. 1994 Nov 1;204(2):854-9.

PMID:
7524242
47.

The 21-aminosteroid tirilazad mesylate protects against endotoxin shock and acute liver failure in rats.

Liu P, Vonderfecht SL, McGuire GM, Fisher MA, Farhood A, Jaeschke H.

J Pharmacol Exp Ther. 1994 Oct;271(1):438-45.

PMID:
7965745
48.
49.
50.

Group B rotavirus VP2: sequence analysis, expression, and gene coding assignment.

Lindsay DA, Vonderfecht SL, Eiden JJ.

Virology. 1994 Feb 15;199(1):141-50.

PMID:
8116237

Supplemental Content

Loading ...
Support Center